Silvernail Andrew K reported acquisition or exercise transactions in this Form 4 filing.
Stryker Corporation director Andrew K. Silvernail received an equity award of 762 Restricted Stock Units (RSUs) of Stryker common stock. Each RSU represents a contingent right to receive one share of common stock. The RSUs vest 100% on the earlier of the 2027 Annual Meeting of Shareholders or May 6, 2027.
Silvernail has voluntarily elected to defer receipt of the shares issuable upon settlement of these RSUs until his departure from the Board of Directors. Following this grant, he directly holds 18,465 shares of Stryker common stock, indicating this is a modest, routine compensation-related award relative to his overall stake.
Stryker Corporation director Rachel Ruggeri received an equity award of 762 shares of Common Stock in the form of Restricted Stock Units (RSUs). The award was granted at no cash cost to her and is classified as a grant or other acquisition, not an open-market purchase.
The RSUs vest in full on the earlier of the date of Stryker’s 2027 Annual Meeting of Shareholders or May 6, 2027. Each RSU represents a contingent right to receive one share of Stryker Common Stock, and following this grant she holds 2,001 shares directly.
McCoy Sherilyn S reported acquisition or exercise transactions in this Form 4 filing.
STRYKER CORP director Sherilyn S. McCoy received an equity grant of 762 Restricted Stock Units. Each RSU represents a right to receive one share of Stryker common stock. The RSUs vest 100% on the earlier of the 2027 Annual Meeting of Shareholders or May 6, 2027.
McCoy has elected to defer settlement of these RSUs, so the corresponding Stryker shares will be delivered on May 1, 2031. After this grant, she holds 7,190 shares of Stryker common stock directly.
Stryker Corporation director Emmanuel Perez Maceda received an equity award in the form of Restricted Stock Units (RSUs). The award covers 762 shares of Stryker common stock and is recorded as a grant/award acquisition, not an open-market purchase or sale.
The RSUs vest in full on the earlier of the company’s 2027 Annual Meeting of Shareholders or May 6, 2027. Each RSU represents a contingent right to receive one share of Stryker common stock. Following this grant, Maceda directly holds 1,322 common shares.
Caforio Giovanni reported acquisition or exercise transactions in this Form 4 filing.
Stryker Corporation director Giovanni Caforio reported an equity award in the form of Restricted Stock Units (RSUs). On May 6, 2026, he received 762 RSUs, each representing a contingent right to one share of Stryker common stock. These RSUs vest 100% on the earlier of the 2027 Annual Meeting of Shareholders or May 6, 2027. Following this grant, Caforio directly holds 4,530 shares of Stryker common stock.
Stryker Corporation director Mary K. Brainerd received an equity award of 762 Restricted Stock Units (RSUs) on May 6, 2026. The grant is a form of stock-based compensation and carries no cash exercise price. After this award, she directly holds 7,790 shares of Stryker common stock.
The RSUs vest in full on the earlier of the 2027 Stryker annual meeting of shareholders or May 6, 2027. Each RSU converts into one share of Stryker common stock when it vests, aligning the director’s compensation with shareholder interests over this period.
Montagnino Kimberly Ann reported acquisition or exercise transactions in this Form 4 filing.
Stryker Corp reported an insider equity award for VP, Chief Communications Officer Kimberly Ann Montagnino. On May 6, 2026, she received 677 Restricted Stock Units (RSUs) of common stock as a compensation grant. These RSUs vest in three equal installments on May 1, 2027, May 1, 2028, and May 1, 2029. Each RSU represents the right to receive one share of Stryker common stock. Following this grant, Montagnino holds 1,872 shares of common stock directly and 33 shares indirectly through a 401(k) plan. The filing shows a routine, non-market grant rather than an open-market purchase or sale.
King Debra reported acquisition or exercise transactions in this Form 4 filing.
Stryker Corp officer Debra King received 1,016 Restricted Stock Units (RSUs) of common stock as equity compensation. The RSUs were granted at no cash cost and increase her direct holdings to 7,569 shares of Stryker common stock, with an additional 8 shares held indirectly through a 401(k) plan.
The 1,016 RSUs vest in three equal installments: one-third on May 1, 2027, one-third on May 1, 2028, and the remaining one-third on May 1, 2029. Each RSU represents a contingent right to receive one share of Stryker common stock as it vests.
Stryker Corporation held its Annual Meeting of Shareholders on May 6, 2026, where shareholders voted on three proposals, including the election of directors. Director nominees generally received strong support, such as Sherilyn S. McCoy with 286,213,500 shares for and 3,785,435 against, and Rajeev Suri with 286,085,744 for and 3,887,285 against, alongside 30,151,420 broker non-votes for each nominee.
Stryker Corporation reported solid first quarter 2026 results with some margin pressure and lower adjusted earnings. Net sales rose 2.6% to $6.0 billion, driven by 5.0% growth in MedSurg and Neurotechnology to $3.2 billion, while Orthopaedics was roughly flat at $2.8 billion.
Reported operating income margin improved to 15.5% and reported diluted EPS increased 14.2% to $1.93. However, adjusted operating income margin narrowed to 21.1%, and adjusted diluted EPS declined 8.5% to $2.60 as non-GAAP adjustments fell versus last year.
The company reorganized its Orthopaedics portfolio into a new Ortho Tech business, combining Mako and related technologies with orthopaedic instruments, which recasts prior segment data without changing consolidated results. Stryker maintained its full year 2026 outlook for 8.0%–9.5% organic net sales growth and adjusted EPS of $14.90–$15.10, citing recovery from a recent cyber incident and continued business momentum.